Outlook Medictors' LYTENAVA 获得英国对湿AMD的核准,每年帮助多达4万名病人。 Outlook Therapeutics' LYTENAVA gets UK approval for wet AMD, aiding up to 40,000 patients yearly.

视野治疗公司已获得英国国家卫生和护理卓越研究所 (NICE) 对LYTENAVA的积极建议,该药物用于治疗湿性老年性黄斑变性 (湿性AMD). Outlook Therapeutics has received a positive recommendation from the UK's National Institute for Health and Care Excellence (NICE) for LYTENAVA, a treatment for wet age-related macular degeneration (wet AMD). 这是全球对LYTENAVA的第一个积极报销决定,每年可为联合王国大约40 000名新患者提供帮助。 This is the first positive reimbursement decision globally for LYTENAVA, which could help around 40,000 new patients annually in the UK. 该公司预计在2025年上半年启动治疗。 The company expects to launch the treatment in the first half of 2025.